Literature DB >> 17314187

CSF neurofilament proteins in the differential diagnosis of dementia.

D de Jong1, R W M M Jansen, Y A L Pijnenburg, W J A van Geel, G F Borm, H P H Kremer, M M Verbeek.   

Abstract

BACKGROUND: Neurofilament (NF) proteins are major cytoskeletal constituents of neurons. Increased CSF NF levels may reflect neuronal degeneration.
OBJECTIVE: To investigate the diagnostic value of CSF NF analysis to discriminate in relatively young dementia patients between frontotemporal lobe degeneration (FTLD) and early onset Alzheimer's disease (EAD; onset < or = 65 years of age), and in elderly dementia patients between dementia with Lewy bodies (DLB) and late onset AD (LAD; onset > 65 years of age).
METHODS: In CSF of 28 FTLD, 37 EAD, 18 DLB and 33 LAD patients, and 26 control subjects, we analysed NF light chain (NFL), phosphorylated NF heavy chain (pNFH), amyloid beta42 protein (Abeta42), total tau and tau phosphorylated at threonine 181 (p-tau181).
RESULTS: CSF NFL levels were higher in FTLD patients compared with EAD patients (p<0.001), and diagnostic accuracy of p-tau181 and Abeta42 analysis improved with addition of NFL analysis (sensitivity 86%, specificity 100%). CSF pNFH levels were elevated in DLB, LAD and FTLD compared with controls (p<0.05) but no significant differences were found between the dementia groups.
CONCLUSIONS: In the diagnostic workup of relatively young dementia patients, CSF NFL levels may play a role in the discrimination between FTLD and EAD, especially in combination with Abeta42 and p-tau181 analysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314187      PMCID: PMC2117885          DOI: 10.1136/jnnp.2006.107326

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid.

Authors:  W J A Van Geel; L E Rosengren; M M Verbeek
Journal:  J Immunol Methods       Date:  2004-12-09       Impact factor: 2.303

Review 2.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

Review 3.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

Authors:  D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

4.  Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF.

Authors:  L E Rosengren; J E Karlsson; J O Karlsson; L I Persson; C Wikkelsø
Journal:  J Neurochem       Date:  1996-11       Impact factor: 5.372

5.  Neurofilament protein levels in CSF are increased in dementia.

Authors:  L E Rosengren; J E Karlsson; M Sjögren; K Blennow; A Wallin
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

6.  Elevated neurofilament levels in neurological diseases.

Authors:  Niklas Norgren; Lars Rosengren; Torgny Stigbrand
Journal:  Brain Res       Date:  2003-10-10       Impact factor: 3.252

Review 7.  Presenile dementia syndromes: an update on taxonomy and diagnosis.

Authors:  M D Greicius; M D Geschwind; B L Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

8.  Neurofilament-immunoreactive neurons in Alzheimer's disease and dementia with Lewy bodies.

Authors:  Claire E Shepherd; Heather McCann; Emma Thiel; Glenda M Halliday
Journal:  Neurobiol Dis       Date:  2002-03       Impact factor: 5.996

9.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

10.  Different variants of frontotemporal dementia: a neuropathological and immunohistochemical study.

Authors:  M Bergmann; K Kuchelmeister; K W Schmid; H A Kretzschmar; R Schröder
Journal:  Acta Neuropathol       Date:  1996-08       Impact factor: 17.088

View more
  40 in total

Review 1.  Applying fluid biomarkers to Alzheimer's disease.

Authors:  Henrik Zetterberg
Journal:  Am J Physiol Cell Physiol       Date:  2017-04-19       Impact factor: 4.249

2.  Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants.

Authors:  Davide Bruno; Nunzio Pomara; Jay Nierenberg; James C Ritchie; Michael W Lutz; Henrik Zetterberg; Kaj Blennow
Journal:  Exp Gerontol       Date:  2011-10-01       Impact factor: 4.032

3.  Neurofilament light chain levels in ventricular cerebrospinal fluid after acute aneurysmal subarachnoid haemorrhage.

Authors:  E R Zanier; D Refai; G J Zipfel; T Zoerle; L Longhi; T J Esparza; M L Spinner; R J Bateman; D L Brody; N Stocchetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-22       Impact factor: 10.154

4.  Fluid Biomarkers of Frontotemporal Lobar Degeneration.

Authors:  Emma L van der Ende; John C van Swieten
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

Review 6.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

7.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

8.  Cerebrospinal fluid analysis should be considered in patients with cognitive problems.

Authors:  Henrik Zetterberg; Niklas Mattsson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-14

Review 9.  Neurofilaments in disease: what do we know?

Authors:  Brian A Gordon
Journal:  Curr Opin Neurobiol       Date:  2020-03-06       Impact factor: 6.627

10.  Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease.

Authors:  Marie-Odile Habert; Leonardo Cruz de Souza; Foudil Lamari; Nelle Daragon; Serge Desarnaud; Claude Jardel; Bruno Dubois; Marie Sarazin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.